Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cebranopadol in Diabetic Peripheral Neuropathy Pain
NCT01939366Phase 2Completed
- Sponsor
- Tris Pharma
- Start
- Sep 2013
- Primary completion
- Jan 2015
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial of cebranopadol in diabetic peripheral neuropathy (DPN) (5 arms), sponsored by Tris Pharma. Primary endpoint: Change in Average Pain Intensity at 6 weeks. Started Sep 2013; status: completed.
02
Drugs
cebranopadol
03
Conditions
diabetic peripheral neuropathy (DPN)
Beyond the preview
Go deeper on NCT01939366.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01939366.